Phase 1 Trial of a Malaria Vaccine
Author Information
Author(s): Mullen Gregory E. D., Ellis Ruth D., Miura Kazutoyo, Malkin Elissa, Nolan Caroline, Hay Mhorag, Fay Michael P., Saul Allan, Zhu Daming, Rausch Kelly, Moretz Samuel, Zhou Hong, Long Carole A., Miller Louis H., Treanor John
Primary Institution: Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America
Hypothesis
Does the AMA1-C1/Alhydrogel+CPG 7909 malaria vaccine improve safety and immunogenicity in humans?
Conclusion
The AMA1-C1/Alhydrogel+CPG 7909 malaria vaccine is safe and highly immunogenic in malaria-naïve individuals.
Supporting Evidence
- Local and systemic adverse events were significantly more likely to be of higher severity with the addition of CPG 7909.
- Anti-AMA1 immunoglobulin G (IgG) levels increased significantly with the vaccine containing CPG 7909.
- The vaccine elicited up to 96% inhibition of parasite growth in vitro.
- Safety profile was acceptable given the enhanced immunogenicity.
- Participants were monitored for adverse events for 180 days post-vaccination.
- Three cohorts were used to assess different doses of the vaccine.
- Significant differences in antibody responses were observed between vaccine groups.
- Further clinical development of the vaccine is ongoing.
Takeaway
This study tested a new malaria vaccine on healthy people and found it to be safe and effective at making their bodies fight malaria.
Methodology
A phase 1 trial with 75 malaria-naive volunteers receiving three vaccinations of different doses of the vaccine.
Potential Biases
Potential bias due to the single-blind design and the specific demographic of participants.
Limitations
The study was limited to healthy volunteers aged 18-45 and may not represent broader populations.
Participant Demographics
Healthy volunteers aged 18-45, malaria-naive.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI 1.72–122.40
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website